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Tools for functional dissection of site-specific
O-GlcNAcylation
Andrii Gorelik †‡a and Daan M. F. van Aalten ‡*ab
Protein O-GlcNAcylation is an abundant post-translational modification of intracellular proteins with the
monosaccharide N-acetylglucosamine covalently tethered to serines and threonines. Modification of
proteins with O-GlcNAc is required for metazoan embryo development and maintains cellular
homeostasis through effects on transcription, signalling and stress response. While disruption of
O-GlcNAc homeostasis can have detrimental impact on cell physiology and cause various diseases, little
is known about the functions of individual O-GlcNAc sites. Most of the sites are modified sub-
stoichiometrically which is a major challenge to the dissection of O-GlcNAc function. Here, we discuss
the application, advantages and limitations of the currently available tools and technologies utilised to
dissect the function of O-GlcNAc on individual proteins and sites in vitro and in vivo. Additionally, we
provide a perspective on future developments required to decipher the protein- and site-specific roles
of this essential sugar modification.
Post(co)-translational protein
O-GlcNAcylation
Post-translational modifications (PTMs) expand the function
and regulation of proteins beyond the genetically encoded
polypeptide. The number of known types of PTMs is close to
several hundred,1 ranging from substantial alterations (proteo-
lytic cleavage resulting in large protein fragments, attachment
of ubiquitin chains, glycosylation with polysaccharides)2–4
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to small tags (phosphorylation, acetylation, methylation,
lipidation).5–8
One of these PTMs, O-GlcNAcylation, is the attachment of a
single O-linked N-acetylglucosamine onto serine and threonine
side chains of intracellular proteins,9 which, in some cases, is
also thought to be co-translational.10 Installation of the sugar
is mediated by the O-GlcNAc transferase (OGT)11,12 on nuclear
and cytoplasmic proteins, covering 10–20% of the whole
human proteome (Fig. 1a).13 The O-GlcNAcase (OGA) opposes
OGT by hydrolysing the O-glycosydic bond to release GlcNAc.14
Thus, a single pair of enzymes makes O-GlcNAc a reversible
and highly dynamic modification that has been implicated in a
myriad of processes such as signalling, metabolism, stress
response and transcription.15
OGT is a family GT41 GT-B glycosyltransferase16 that
consists of a 13.5 tetratricopeptide repeat (TPR) domain and
a Rossman-like catalytic domain (Fig. 1b).17 Although the
13.5-TPR OGT is the major isoform, two additional isoforms
may arise from alternative splicing and alternative start codons:
a truncated OGT with 2.5 TPRs localised in the nucleus and
cytoplasm and a 9.5-TPR OGT containing a mitochondrial
targeting sequence.18,19 The function of the latter two isoforms
is unclear. Moreover, it appears that full-length nucleocyto-
plasmic OGT is sufficient for O-GlcNAcylation of mitochondrial
proteins.20 O-GlcNAc transfer by OGT involves an ordered bi-bi
catalytic mechanism: binding of the donor sugar nucleotide
UDP-GlcNAc is followed by the target protein acceptor
substrate.17,21 A second catalytic activity of OGT, host cell
factor-1 (HCF-1) cleavage, is performed in the same active
site and results in proteolytic maturation of this transcriptional
co-regulator.22 More recently, OGT was shown to possess a third
(and unexpected) activity – catalysis of S-GlcNAc transfer onto
cysteines.23,24 Although the crystal structures of the TPRs
and the truncated OGT have been solved (Fig. 1b),17,25 the
full-length OGT structure is yet to be determined and may
provide a further understanding of how OGT recognizes its
substrates. The TPR domain of OGT mediates substrate recog-
nition through a so-called asparagine ladder.17 Using protein
microarrays and mutational analysis, the five asparagines in
the lumen of the TPR domain have been shown to contribute
to the binding of OGT protein substrates beyond its active
site.26,27 Recently, additional aspartates in the TPR domain
that influence recognition of some OGT substrates have been
identified.28 OGT does not utilise a defined motif for
O-GlcNAcylation. However, in a high-throughput screen a pre-
ferred O-GlcNAc sequon has been determined as T-P-V-gS/T-R-
A12 which is in good agreement with P-X-gT-X-A and P-V-gS29
and P/V-P/V-V-gS/T-S/T,30,31 previously identified in large-scale
proteomics studies.
OGA is a GH84 family glycoside hydrolase16 consisting of an
N-terminal catalytic domain and a histone acetyltransferase
(HAT)-like domain separated by a disordered region and a stalk
Fig. 1 O-GlcNAc cycling on nucleocytoplasmic proteins. (a) OGT and OGA control the addition and removal of GlcNAc on serine and threonine
residues. (b) Domain architecture and structures of OGT (composite of PDB: 1W3B and PDB: 5C1D) and OGA (PDB: 5M7R, lacks the disordered region).
Catalytic site residues K842 (OGT) and D175 (OGA) are coloured in red. GT domain – glycosyltransferase domain. NLS – nuclear localization sequence,40
GH domain – glycoside hydrolase domain.
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domain (Fig. 1b). The HAT-like domain lacks the ability to bind
acetyl coenzyme A (the substrate for acetylation) and its role
remains enigmatic.32 The putative short human OGA isoform
lacks the HAT-like domain and a portion of the stalk domain,
resulting in reduced activity due to the inability to form a
functional dimer.33 Overexpression of this isoform with a GFP
tag results in its localisation to lipid droplets.34 However, the short
OGA isoform has not been detected at an endogenous protein
level. The first crystal structures of a monomeric bacterial ortho-
logue of human OGA from Clostridium perfringens (CpOGA) in
complex with its substrate peptides exhibited a V-shaped peptide
conformation in the active site.35,36 Later it was shown that
human OGA forms a dimer with a substrate-binding cleft where
O-GlcNAc peptides assume the same V-shaped conformation
upon binding in the active site, confirming the findings obtained
with CpOGA.33,37,38 While the interactions of OGA active site
residues with GlcNAc are conserved, exactly how (and whether)
protein substrates bind beyond the active site is unknown.39 OGA
itself contains a single O-GlcNAcylation site at Ser405, which may
regulate OGA stability.24
The roles of O-GlcNAc on proteins have been studied in
animal models (such as mice and fruit flies), where OGT deletion
is lethal and causes severe developmental abnormalities.41–43
Excess of O-GlcNAc can also have negative impact on normal cell
physiology as OGA knockout is lethal in mice,44 whereas
increased O-GlcNAc levels have been linked to oncogenic
reprogramming.45 Since its discovery, the relationship between
O-GlcNAcylation and phosphorylation has been closely studied
due to the frequent occurrence on the same or adjacent Ser/Thr
residues which results in mutual regulation.46 The role of
O-GlcNAc in stress response is exemplified by its participation
in stress granule formation and oxidative stress.47 At individual
protein level, lack of O-GlcNAc on tau and a-synuclein has
been associated with pathological brain conditions such as
Alzheimer’s and Parkinson’s disease.48,49 Moreover, O-GlcNAc
can mediate transcription through modification of RNA Poly-
merase II50 and regulate autophagosome maturation by
modifying SNAP29 depending on the cellular metabolic state.51
Transcriptionally, OGT expression can be decreased through
nuclear degradation of an intron-retained OGT transcript
in response to high overall O-GlcNAcylation levels to maintain
O-GlcNAc homeostasis.52 Similar to OGT, OGA expression is
also responsive to the modulation of overall O-GlcNAc modifi-
cation. Pharmacological inhibition of OGA in cells increases
total O-GlcNAcylation levels, while also increasing OGA expres-
sion and decreasing expression of OGT as a compensatory
mechanism.53
Recently, ogt missense mutations associated with X-linked
intellectual disability have been identified.54 These occur in the
TPR domain of OGT54–56 as well as in the catalytic domain.57,58
Some of these mutations cause a decrease in endogenous
OGT activity.55,57 Therefore, it is possible that abolished
O-GlcNAcylation status on a subset of OGT substrates or even
a single substrate/site could contribute to the intellectual dis-
ability phenotype, an avenue that is currently being explored in
our laboratory using several methods discussed in this review.
Currently, the O-GlcNAc field is experiencing rapid growth
with researchers from related disciplines discovering that
O-GlcNAc modulates the function of their proteins of interest.
Examples include discoveries of the role of O-GlcNAcylation in
preventing the aggregation of a Polycomb member, polyhomeotic,
in Drosophila,59 as well as in controlling the anti-inflammatory
function on receptor-interacting serine/threonine-protein kinase 3
(RIPK3)60 and in activating phosphoglycerate kinase 1 (PGK1) to
promote glycolysis,61 to name a few. As the roles of O-GlcNAc are
becoming recognized, there is an emerging need for tools to
dissect site-specific O-GlcNAcylation.
Visualisation of protein- and site-specific O-GlcNAcylation
A crucial step in studying any PTM is its detection. Although
mass spectrometry (MS) provides a high-throughput method
for O-GlcNAc identification and site-mapping (reviewed
elsewhere62), it is complicated by time-consuming sample
preparation, expensive equipment and (often difficult) analysis.
Therefore, the use of gel and western blot methods is generally
required which will be discussed below.
In the early days of the field, O-GlcNAc was detected by
galactosyltransferase labelling with an [3H]-galactose followed
by autoradiography and by lectin binding (for instance, with
fluorescently labelled wheat germ agglutinin, which binds
terminal GlcNAc residues).63,64 This was later surpassed by a
superior chemoenzymatic method based on the mutant b-1,4-
galactosyltransferase (GalTY289L) that transfers an azide deriva-
tive of GalNAc (GalNAz) onto O-GlcNAcylated proteins.65 The
azide provides a reactive handle for the attachment of tags
using copper-catalysed azide–alkyne cycloaddition (CuAAC)
or copper-free strain-promoted azide–alkyne cycloaddition
(SPAAC),66,67 allowing qualitative and quantitative detection of
O-GlcNAc.66,68 The use of mass tags (such as polyethylene glycols
PEG5000- or PEG2000-alkyne) allows resolution of GlcNAc-
modified proteins on a gel and determination of absolute stoi-
chiometry using a western blot with an antibody against the target
protein (eliminating the need for pulldowns and O-GlcNAc-
specific antibodies).66 Additionally, the number of bands shifted
indicates the number of O-GlcNAc sites. Unfortunately, the
detection limit of the PEGylation method is approximately 5%
(depending on the quality of the antibody) and the labelling
efficiency relies on full completion of the galactosyltransferase
reaction.66 The efficiency of the subsequent chemical addition of
a PEG mass tag may also vary depending on the reagent concen-
tration. To address this issue, the SPAAC reaction has been
optimised using a synthetic protein standard (bearing stoichio-
metric O-GlcNAc modification) and commercial reagents.69 As an
alternative to mass tagging, a native polyacrylamide gel electro-
phoresis (native PAGE) method based on co-polymerised CpOGA
has been developed in our laboratory (C. Fu and D. M. F.
van Aalten, Analyst, in press). The retardation of an O-GlcNAc-
modified band happens as a result of high-affinity binding by the
catalytically inactive CpOGA. Conveniently, this approach does not
require any chemical modification of the sample.
Sometimes the stoichiometry of O-GlcNAc on a given protein
is below the detection limit of antibodies. In order to amplify
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the O-GlcNAc signal in such cases, a proximity-ligation based
method has been developed. First, O-GlcNAc is chemoenzyma-
tically labelled with GalNAz, followed by a reaction with an
alkyne-biotin. The next step is the coupling of antibody-DNA
conjugates targeted to either biotin or the protein of interest. If
the protein is O-GlcNAcylated, the antibodies are brought into
proximity, leading to ligation of DNA tags. qPCR is subse-
quently performed to quantify the signal.70 While this method
allows detection of O-GlcNAcylated proteins in small amounts
of sample, the specificity of O-GlcNAc signal heavily relies on
the specificity of an antibody against a protein of interest which
could otherwise detect off-targets.
The donor substrate promiscuity of OGT has been exten-
sively exploited to generate various metabolic reporters for
global O-GlcNAc profiling by mass-spectrometry and in-gel
visualisation. These modified sugars can be fed to cells where
they enter specific metabolic pathways and can be utilised by
OGT as donor substrates. These include GlcNAc derivatives
with alkyne and azide functionalities such as GlcNAz,71
GlcNAlk,72 6AzGlcNAc,73 4-deoxy-GlcNAz,74 2AzGlc,75 6AlkGlcNAc,76
6AzGlc77 and GlcNDAz.78
Antibodies remain the most popular tool to detect O-GlcNAc.
The two most widely used pan-specific O-GlcNAc antibodies are
RL2 (originally developed for detecting nuclear pore proteins)64,79
and CTD110.6 (developed based on the O-GlcNAcylated RNA
polymerase II C-terminal domain).80 Although both of these
commercially available antibodies are monoclonal, RL2 exclu-
sively binds to O-GlcNAc, while CTD110.6 may also recognise
N-GlcNAc, GlcNAcylated O-mannose, cross-reacts with terminal
b-GlcNAc on complex N-glycans of cell surface glycoproteins
and more recently has been shown to efficiently detect
S-GlcNAc on cysteines.24,81–84 Therefore, care must be taken
when using CTD110.6 antibody whose specificity must be
tested in each case with an OGA-treated negative control.
Although RL2 binds O-GlcNAc with greater specificity, it may
not recognise O-GlcNAcylation in certain contexts such as
demonstrated with a-synuclein stoichiometrically O-GlcNAc-
modified at several reported O-GlcNAcylation sites.85
Unlike in the field of phosphorylation, very few site-specific
O-GlcNAc antibodies have been generated. Nevertheless,
these have greatly aided the study of site-specific O-GlcNAc
modification and are summarised in Table 1. For instance,
reciprocal interplay between O-GlcNAcylation and proximal
phosphorylation could be examined using antibodies against
O-GlcNAcylated Thr58 on c-Myc (first site-specific O-GlcNAc
antibody ever produced)86 and O-GlcNAcylated Ser400 on tau.46
Our laboratory had generated a Ser395-O-GlcNAc-specific TGF-b
activated kinase-1 (TAK1) binding protein-1 (TAB1) antibody that
revealed increased O-GlcNAcylation as a modulator of TAK1
signalling upon IL-1 stimulation and osmotic stress.87 More
recently, we produced a Ser517-O-GlcNAc-specific CRMP2 antibody
to show an age-dependent increase in CRMP2 O-GlcNAcylation
associated with short-term memory impairment.88
Enzymatic methods for generating protein-specific
O-GlcNAcylation
Access to stoichiometrically modified proteins is often required
to dissect the mechanistic consequences of PTMs in vitro and
in vivo. However, producing highly O-GlcNAc-modified proteins
is challenging. Traditionally, the simplest approach to obtain
an O-GlcNAcylated protein of interest has been in vitro reaction
with OGT (Fig. 2a).96 Despite the ease of implementation, to
achieve high O-GlcNAc stoichiometry, long incubation times
are generally needed which in itself may have undesired effects
on the stability of the protein under investigation. Alternatively,
to preserve protein stability, OGT can be co-expressed with its
substrates in E. coli or insect cells (Fig. 2b). Application of this
system in a bacterial setting has been demonstrated for the
RNA-Polymerase II C-terminal domain, TAB1, calcium/
calmodulin-dependent protein kinase type IV (CaMKIV), Tau,
Coactivator Associated Arginine Methyltransferase 1 (CARM1)
and nuclear pore glycoprotein p62 (nup62).96–98 However, an
endogenous glycosidase in E. coli may compromise the yield of
the O-GlcNAc-modified proteins produced with this approach.99
In insect (Sf9) cells simultaneous expression of CREB and OGT
led to a three-fold increase of CREB glycosylation to almost
90%.66 Although this co-expression approach may not be com-
patible with all OGT substrates, the main advantage is the ability
to produce co-translationally O-GlcNAc-modified proteins which
is impossible via OGT reaction in vitro.
Recombinant O-GlcNAc-modified protein on its own is
usually not sufficient to dissect the function of this modification.
Table 1 Site-specific O-GlcNAc antibodies generated to date
O-GlcNAc antibody Site (human) Ref.
c-Myc Thr58 86
Collapsin response mediator protein-2 (CRMP2) Ser517 88
Histone H2A Ser40 89
Histone H2A Thr101 www.glycoscientific.com/
Histone H2B Ser112 90
Histone H3 Thr32 www.glycoscientific.com/
Histone H4 Ser47 www.glycoscientific.com/
Insulin receptor substrate-1 (IRS1) Ser1011 91
Insulin receptor substrate-2 (IRS2) Thr1155 www.glycoscientific.com/
NAD-dependent protein deacetylase Sirtuin-1 (SIRT1) Ser549 92
Tau Ser400 93 and 94
TGF-beta-activated kinase 1-binding protein 1 (TAB1) Ser395 87
TGF-beta-activated kinase 1-binding protein 3 (TAB3) Ser408 95
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To acquire control over a single-protein O-GlcNAcylation status
in a complex cellular environment, a creative way to induce
proximity of OGT to its substrates in cells has been proposed
recently (Fig. 2c).100 Exploiting the fusion of OGT to a nanobody
against a tag (GFP or RFP) on a protein of interest or a nano-
body against endogenous protein target, Woo and colleagues
managed to increase O-GlcNAcylation stoichiometry on a sub-
set of OGT substrates. In its current form this proximity
induction relies on the overexpression of OGT which concomi-
tantly elevates global O-GlcNAc levels. This strategy may have
potential to increase O-GlcNAcylation on a protein of interest, if
the impact of OGT overexpression on the global O-GlcNAcome
can be addressed. Alternatively, other proximity approaches
could be explored, such as the use of aptamers or small
molecules (PROTAC principle). For example, the use of a
heterobifunctional small molecule has already been utilised
to bring protein phosphatase 1 (PP1) in proximity to its targets
resulting in a protein-specific decrease in phosphorylation of
AKT kinase and EGFR.101 One of the most important considera-
tions for the future development of such probes is that the
interaction of the proximity-inducing molecules does not affect
the catalytic or scaffolding function of OGT or its substrate.
Current methods to increase protein-specific O-GlcNAcylation
still result in heterogeneous mixtures of modified and unmodified
proteins and make functional analysis particularly cumbersome
in case of multiple glycosylation sites. Thus, knowledge of specific
O-GlcNAc sites and application of approaches to generate site-
specifically O-GlcNAcylated proteins could circumvent this issue.
Chemical biology methods for dissecting site-specific
O-GlcNAcylation in vitro
One approach that has been explored to incorporate site-
specific O-GlcNAcylation is expressed protein ligation (EPL), a
semi-synthetic strategy to obtain homogenous and stoichio-
metric site-specific PTMs of a target protein (Fig. 3a).102,103 EPL
involves synthesis of a peptide bearing a desired functionality
(e.g. post-translational modification), which is then ligated via
S-to-N acyl-transfer to a thioester generated from a recombinant
intein-fusion protein.102 To date, tau,104 a-synuclein,49,85,105
HSP27106 and an unnaturally modified ubiquitin69 are the only
four reported O-GlcNAcylated proteins produced using EPL.
This method has been used to dissect the mechanistic con-
sequences of O-GlcNAcylation on a-synuclein (Thr72, Thr75,
Thr81, Ser87),49,85,105 which is a small (o15 kDa) protein
amenable to EPL. This approach revealed that O-GlcNAc on
a-synuclein affects aggregation and toxicity in vitro.85 Apart
from a handful of O-GlcNAcylated proteins, S-GlcNAcylated
casein kinase 2 (CK2)107 and a-synuclein108 have been produced
by EPL in order to increase the stability of the modification against
hydrolysis. Through structural and biophysical studies it was
shown that S-GlcNAc serves as a good non-hydrolysable analogue
for O-GlcNAc that can be recognized by some O-GlcNAc-specific
antibodies (Ser395-O-GlcNAc-TAB1 and CTD110.6).24,108
In future the utility of CHF or CF2 functionalized GlcNAc as
potentially nonhydrolyzable analogues for EPL could be investi-
gated as these have been shown to be good steric and electronic
representations in the context of O-phosphorylation.109 The
main disadvantage of EPL is that it must be optimised for every
protein and the maximum length of the peptide for ligation is
Fig. 2 Methods for generating protein-specific O-GlcNAcylation. (a)
In vitro OGT reaction. (b) Co-expression of OGT with its substrate in
E. coli, followed by purification. KanR – kanamycin resistance, AmpR –
ampicillin resistance. (c) Proximity OGT approach for protein-selective
O-GlcNAcylation in cells.100 nGFP – anti-GFP nanobody. Blue squares
denote O-GlcNAc.
Fig. 3 Site-specific chemical biology approaches to study O-GlcNAcylation in vitro. (a) Expressed protein ligation. (b) ‘‘Tag-and-modify’’ dehydroalanine
approach. POI – protein of interest.
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currently limited. Importantly, this method requires good
expression of a soluble intein-fusion protein, which frequently
poses a problem. Insertion of modified peptides into the central
portions of large, globular proteins involves iterative ligation
steps and is particularly challenging. A cysteine residue that EPL
introduces at the site of ligation cannot always be converted to a
native amino acid (e.g. to alanine via desulphurisation). There-
fore, the site of ligation must be carefully considered.
In another approach, taking advantage of the potent nucleo-
philicity and low abundance of cysteine in proteins, cysteine-
conversion chemical methods have been developed by Davis
and co-workers to obtain proteins with site-specific O-GlcNAc
mimics in vitro (Fig. 3b).110–112 These rely on the chemical
transformation of a genetically installed cysteine into dehydro-
alanine by an alkylating reagent (for example, O-mesitylenesulfonyl-
hydroxylamine (MSH) or 2,5-dibromohexanediamide (DBHDA))
under denaturing conditions. The dehydroalanine of the unfolded
protein is then incubated with a reactive GlcNAc derivative (e.g.
GlcNAc-thiol) and the modified protein is refolded.110–112 Nota-
bly, a thiol-linked GlcNAc prepared in such a way is resistant to
reduction by DTT.113 Moreover, endoglycosidase-A exhibits
trans-glycosylation activity for a synthetic S-linked GlcNAc
(S-GlcNAc)-modified protein with a high modification efficiency.112
Cys-S-GlcNAcylation at position 101 (Thr in the native protein) of
histone H2A was shown to destabilise H2A/H2B dimers, promoting
an open chromatin state. Installation of S-GlcNAc at position 112 of
histone H2B (Ser in the native protein) allowed identification of
interactors, among which are subunits of the FACT chromatin
remodelling complex.110,111 As evidence for physiological mimicry,
O-GlcNAc-homohomo-Ser prepared by this approach can be hydro-
lysed by human OGA.114 This method is limited to recombinant
proteins with no or few native cysteine residues, that otherwise must
first be substituted by other amino acids (Ser or Ala). Furthermore,
this approach does not allow control of stereo-specificity of the
modification rendering it difficult to interpret the results of the
experiment.
Another method for installing S-GlcNAc employs a thio-
glycoligase capable of transferring GlcNAc to cysteines, engineered
from a Streptomyces plicatus hexosaminidase via mutation of the
catalytic glutamate (E314A).115 Withers and co-workers managed to
produce S-GlcNAcylated synuclein peptides and tau protein using
this new method.115 As with the dehydroalanine approach, this
technique requires mutation of all native cysteines that are not
destined for S-GlcNAc modification and its utility is limited to
in vitro reactions.
Genetic methods for dissecting site-specific O-GlcNAcylation
in vivo
Loss-of-function mutations are the most common approach
to probe site-specific O-GlcNAcylation in cultured cells (e.g.
Ser/Thr mutation to Ala). For example, Ser529Ala mutation
on phosphofructokinase 1 was shown to prevent O-GlcNAc-
dependent increase in its activity,116 while Thr228Ala mutation
of Oct4 reduces stem cell self-renewal and reprogramming.117
The caveat of this approach lies in the loss of the side chain
which in itself could have an impact on protein folding and
stability. Therefore, Ala mutagenesis is often used in combi-
nation with other methods to down- or upregulate OGT or OGA
levels and their enzymatic activity. OGA knockout, knockdown
and inhibition is an effective way to elevate total O-GlcNAc
modification levels in vivo and in cell culture, since
O-GlcNAcylation is often sub-stoichiometric in cells (o10%)
due to the high OGA activity.118–120 However, with this approach,
functional dissection of the roles of individual O-GlcNAc sites is
impeded by potential ambiguous phenotypes through effects on
many other OGT substrates.
Genetic code expansion (GCE) technology allows site-
specific incorporation of unnatural amino acids (including
PTMs) in vitro and in vivo by utilising evolved orthogonal amber
suppressor tRNA synthetases (Fig. 4a).121–125 The GCE method
often requires evolution of an archaeal pyrrolysine-tRNA
synthetase (PylRS) to aminoacylate a corresponding amber
suppressor tRNA, which in turn allows decoding of the
unnatural amino acid (UAA) of interest at an amber stop (or
quadruplet121) codon in a genetically predetermined fashion
(Fig. 4a). Since the amber codon is the least abundant of the
three stop codons, its use reduces the off-target incorporation
of the amino acid where endogenous amber stop codons occur.
Co-translational incorporation of a glycosylated amino acid
by the GCE technology could become a promising tool to site-
specifically examine the gain-of-function O-GlcNAc modifica-
tion in vivo.122–124 With over 200 UAAs incorporated to date,126
the expanded genetic code includes several PTMs such as
phosphorylated amino acids (serine, threonine and tyrosine),
acetylated lysine and a scaffold for ubiquitin- and SUMO-
modified lysine.127–132 Most of the UAAs incorporated by the
PylRS-based GCE are lysine derivatives that resemble the natural
substrate of PylRS, pyrrolysine.126 Amino acids as polar as
GlcNAcylated serine or cysteine have not yet been added to the
expanded genetic code. Apart from the specificity and activity of
the evolved PylRS, incorporation of UAAs largely depends on the
tolerance of the corresponding aminoacylated tRNA by the trans-
lation machinery, such as the ribosome, elongation factor Tu and
release factors. These problems were previously encountered with
phosphoserine, for which some components of the translational
machinery had to be additionally engineered.128
A major obstacle in applying GCE to O-GlcNAc is the uptake
and stability of the synthetic O-GlcNAcylated amino acid. E. coli,
which is used as a host system for evolving PylRS, metabolises
Ser-O-GlcNAc as a carbon source,133 precluding the use of this
UAA for GCE.134 De-acetylation of a per-O-acetylated Ser-O-GlcNAc
variant (which would hypothetically increase the cellular uptake)
does not occur in E. coli as it does not express the requisite
deacetylases.133 The latter strategy would be more suited to
mammalian cells, where pan-specific de-acetylating enzymes
do exist. Importantly, however, we showed that a synthetic
amino acid Cys-S-GlcNAc, a Ser-O-GlcNAc analogue, is effi-
ciently internalised by E. coli where it remains metabolically
stable, satisfying the first essential step and prerequisite for
directed evolution of PylRS.135
Recombinant proteins with a glycosylation mimic have been
obtained indirectly through PylRS amber suppression, by
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introducing an amino acid with the alkene functionality
followed by a click chemistry reaction.136 Recently, cellular
incorporation of dehydroalanine was demonstrated.137 This
allowed the authors to install thio-linked GlcNAc at a defined
position on GFP which was recognised by a pan-specific
O-GlcNAc antibody.137
Although glycosylated amino acids have not been incorporated
by GCE, there are some clues as to the feasibility of this approach
reported in several studies.138,139 In these reports glycosylated
recombinant proteins were produced in a cell-free system using
chemically aminoacylated amber suppressor tRNAs.138,139 While
the efficiencies of amber suppression varied between different
glycosylated amino acids reaching up to 30%,138 in one of the
studies, it was shown that Thr-O-GalNAc could be incorporated
only at the protein N-terminus, suggesting that glycosylated
polypeptides are not well tolerated by the ribosome.139
The major advantage of GCE is the ability to produce
stoichiometrically-modified proteins in living systems. On the
other hand, the level of incorporation strongly depends on the
suppression efficiency of the stop codon. This does not pose
significant issues for purified recombinant proteins (where the
expression can be scaled up). However, when interpreting the
effects of a post-translational modification in vivo, it is challen-
ging to provide appropriate controls (i.e. achieving the same
expression as for the unmodified protein). Therefore, any
observed effects resulting from incorporation of a UAA could
also be the result of altered expression levels. Undesired off-
target effects could also be observed in case of mis-incorporation
of the amino acid in unintended proteins in place of endogenous
stop codons, resulting in skewed phenotypes. Future develop-
ments of GCE are required to address these issues.
To gain insight into site-specific O-GlcNAcylation in cells,
our laboratory has explored a surprisingly simple approach to
genetically introduce a non-hydrolysable S-GlcNAc in vitro and
in vivo using Ser/Thr to Cys mutagenesis and relying on the
fortuitous promiscuity of OGT that happens to possess efficient
S-GlcNAc transferase activity (Fig. 4b).24 Notably, this method
does not require any exogenous biomolecular machinery, over-
expression of (mutant) genes or chemical synthesis and can be
combined with the CRISPR-Cas9 genome editing technology.
With this approach, the stoichiometry of cysteine GlcNAcylation
can replicate that of OGA inhibition in cells due to the hydrolytic
stability of S-GlcNAc. However, unlike OGA inhibition, S-GlcNAc
mutagenesis does not affect global O-GlcNAc levels, minimizing
undesired indirect effects. By applying this method to a single
Ser O-GlcNAcylation site on OGA and converting it to a Cys
S-GlcNAcylation site, we managed to increase the stoichiometry
almost five-fold (from 15% to over 70%), similar to that achieved
with the OGA inhibitor treatment.24 We showed that the high
GlcNAcylation stoichiometry decreased OGA stability in cells,
while the overall thermal stability remained unchanged relative
to the wild type protein.24 Interestingly, in the same sequence
contexts S-GlcNAc appears to be more stable to CID MS/MS
fragmentation23 and may assist in mapping and detection
of O-GlcNAc sites. Additionally, homogenous site-specifically
S-GlcNAcylated recombinant proteins can be produced through
GlcNAcylation of a Cys mutant protein and subsequent treat-
ment with OGA (for example, the highly-active CpOGA) to remove
unwanted O-GlcNAcylation (if multiple modification sites are
present). It must be noted that in cases where OGA inhibition
does not elevate O-GlcNAcylation levels on a protein of interest
in cells, this approach may not be applicable. While this
Fig. 4 Approaches to study site-specific O-GlcNAcylation in vivo. (a) Principle of a genetic code expansion approach with a metabolically stable Cys-S-
GlcNAc amino acid: (1). UAA uptake, (2). tRNA aminoacylation, (3). UAA translation in response to a stop codon, (4). Production of a modified protein. (b)
Genetic recoding approach to introduce site-specific S-GlcNAc mimicry of O-GlcNAcylation.24 Blue squares denote GlcNAc. POI – protein of interest.
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S-GlcNAc genetic recoding approach has been applied in cultured
human and mouse cells, it has yet to be demonstrated that this
leads to site-specific S-GlcNAc incorporation in animal models.
Conclusions
The functional consequences of protein O-GlcNAcylation still
remain poorly understood due to the limited number of tools
to study its site-specific effects. As can be appreciated from
this review, no single method to study protein- and site-specific
O-GlcNAcylation can be universally applied and all of the
discussed techniques have their advantages and disadvantages.
Thus, a combination of these approaches can help us achieve a
comprehensive understanding of the functions of the O-GlcNAc
PTM on specific proteins and sites. The future developments in the
field require optimization of contemporary methods and invention
of new strategies to gain control of protein- and site-specific
modification. Expanding the genetic code with glycosylated amino
acids would represent just one of these future advances. Ingenious
methods are required to achieve protein- and site-specific
O-GlcNAcylation with minimal side effects and to avoid unneces-
sary non-physiological perturbation in living systems. The use
of non-hydrolysable analogues of O-GlcNAc (such as S-, CHF- and
CF2-linked GlcNAc or other analogues
24,74,140) in an intracellular
setting must be considered to withstand the high activity
of OGA that could otherwise abolish the efforts of site-specific
installation of O-GlcNAc. Spatiotemporal control of site-specific
O-GlcNAcylation in cells is also important, since O-GlcNAc is a
signalling molecule that can lead to rapid activation of signalling
cascades. Last but not least, low O-GlcNAcylation stoichiometry at a
given site can be the result of protein–protein interactions that
‘‘mask’’ such modification sites and prevent subsequent post-
translational modification by OGT, thus requiring implementation
of techniques for co-translational site-specific GlcNAc incorpora-
tion. Bridging the gap between chemistry and biology is required to
invent approaches that fine-tune O-GlcNAc stoichiometry with a
single protein and amino acid residue precision. Such interdisci-
plinary amalgamation will be instrumental in investigating the
diverse functions of protein O-GlcNAcylation.
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